secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001789769-22-000096
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q3 net loss $56.2M; DELTA-1 trial paused; CMO resigns
----------------------------------------------------------------

- Q3 net loss $56.2M ($0.43/share); cash & securities $303.3M at Sept 30, down from $454.1M at Dec 31, 2021.
- DELTA-1 trial voluntarily paused due to manufacturing contamination; FDA notified; update expected Q1 2023.
- DELTA-2 enrollment deferred; first patient dosed with ITIL-306 (CoStAR-TIL) for NSCLC; clinical data expected in 2023.
- Dr. Robert Hawkins appointed Head of R&D; Dr. Zachary Roberts resigned as CMO effective Nov 11, 2022.
- Cash runway into 2025 expected with planned sale-leaseback of Tarzana manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000096/0001789769-22-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000096/til-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001789769-22-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer